Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Insightec Announces First Glioblastoma Patient Completed Chemotherapy Cycles With Blood Brain Barrier Disruption Using Focused Ultrasound in Yonsei University | ||
By: PR Newswire Association LLC. - 31 Jan 2019 | Back to overview list |
|
HAIFA, Israel and SEOUL, South Korea, January 31, 2019 /PRNewswire/ -- INSIGHTEC®, a global medical technology innovator of incisionless surgery, and Yonsei University announced today that the first patient worldwide completed chemotherapy cycles in a clinical trial to investigate the safety and efficacy of focused ultrasound for disrupting the blood brain barrier (BBB) in patients with glioblastoma (GBM). This first patient successfully completed all six sessions of their planned complete adjuvant temozolomide (TMZ) with BBB disruption treatment. There were no complications or side effects following disruption of the BBB with focused ultrasound. Glioblastoma is the most common primary malignant brain tumor in adults[1]. The blood brain barrier not only protects the brain from toxins, it also prevents the effective delivery of therapeutic agents to treat brain tumors, such as GBM, which is why disrupting the BBB is key for introducing treatment options. "This is the world's first complete treatment using low frequency focused ultrasound to temporarily increase the permeability of the BBB in a glioblastoma patient during adjuvant TMZ and allow the passage of a therapeutic agent," commented Jin Woo Chang, MD, PhD, Professor in the Department of Neurosurgery, Director of the Brain Research Institute at Yonsei University College of Medicine and the trial's principal investigator. "Clinical research such as this is critical to evaluating the potential of new technologies." The investigational Exablate Neuro device from INSIGHTEC delivers low frequency focused ultrasound without surgical incisions to temporarily disrupt the BBB. In the clinical trials, following surgical resection and radiotherapy plus concomitant TMZ, focused ultrasound is delivered during the first treatment of each of the six maintenance cycles of TMZ. "This trial is a strong example of the brightest researchers exploring new frontiers in neuroscience," said Maurice R. Ferré MD, INSIGHTEC's CEO and Chairman of the Board. "INSIGHTEC's focused ultrasound technology has the potential to break down the barriers to treatments in the brain such as glioblastoma with the ultimate goal of improving patient lives." About INSIGHTEC For more information, please visit: http://www.insightec.com [1] http://braintumor.org/brain-tumor-information/understanding-brain-tumors/tumor-types/ Contact details: |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |